Division of Gastroenterological Surgery, Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Japan.
Division of Gastroenterological Surgery, Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Japan;
Anticancer Res. 2021 Apr;41(4):2141-2145. doi: 10.21873/anticanres.14986.
BACKGROUND/AIM: We compared the outcome of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for unresectable locally advanced thoracic esophageal cancer (EC) with that of cisplatin (CDDP) and 5-fluorouracil (5-FU) as combination chemoradiotherapy (CF-RT) in clinical settings.
Seventy-three patients with unresectable locally advanced thoracic EC were included in this study. CF (n=38) consisted of intravenous CDDP at 70 mg/m (day 1) and 5-FU at 700 mg/m (days 1 to 4), repeated every four weeks for two cycles. DCF (n=35) consisted of intravenous docetaxel at 50 mg/m (day 1), CDDP at 60 mg/m (day 1), and 5-FU at 600 mg/m (days 1 to 4), repeated every four weeks for two cycles. Patients were irradiated with 60 Gy in 30 fractions.
The overall complete response (CR) rate of DCF-RT was significantly higher than that of CF-RT (36.7% vs. 3.7%, p=0.003). The 3-year overall survival (OS) rate of DCF-RT was significantly higher than that of CF-RT (32.8% vs. 8.5%, p<0.001).
DCF-RT demonstrated a higher CR rate and OS for unresectable locally advanced thoracic EC than CF-RT.
背景/目的：我们比较了多西他赛、顺铂和 5-氟尿嘧啶联合放化疗（DCF-RT）与顺铂（CDDP）和 5-氟尿嘧啶（5-FU）联合放化疗（CF-RT）在不可切除局部晚期胸段食管鳞癌（EC）患者中的疗效。
73 例不可切除局部晚期胸段 EC 患者纳入本研究。CF 组（n=38）方案为静脉滴注顺铂 70mg/m（第 1 天）和 5-氟尿嘧啶 700mg/m（第 1 至 4 天），每 4 周重复 2 个周期。DCF 组（n=35）方案为静脉滴注多西他赛 50mg/m（第 1 天）、顺铂 60mg/m（第 1 天）和 5-氟尿嘧啶 600mg/m（第 1 至 4 天），每 4 周重复 2 个周期。患者接受 60Gy 分 30 次照射。
DCF-RT 的总体完全缓解（CR）率明显高于 CF-RT（36.7% vs. 3.7%，p=0.003）。DCF-RT 的 3 年总生存率（OS）明显高于 CF-RT（32.8% vs. 8.5%，p<0.001）。
与 CF-RT 相比，DCF-RT 可提高不可切除局部晚期胸段 EC 的 CR 率和 OS。
